Giredestrant plus Afinitor lowered the risk of cancer worsening or death by 62% in patients with ESR1-mutated, ER-positive, HER2-negative advanced breast cancer.
|Articles|July 8, 2020
The Latest News and Updates in Kidney Cancer
Author(s)Ryan McDonald
A roundup of the latest news and updates for patients with Renal Cell Carcinoma from CURE®.
Advertisement
Known as the most common form of kidney cancer in adults, renal cell carcinoma (RCC) has seen an influx of research in recent weeks. Here, CURE® looks back at some of the latest news and updates in the RCC space.
- Data presented at the 2020 ASCO Virtual Scientific Meeting demonstrated that MK-6482 appeared to be well tolerated and induced clinical responses among patients with VHL—associated RCC.
- Updated study results also presented during the 2020 ASCO Virtual Scientific Meeting showed that Keytruda (pembrolizumab) in combination with Inlyta (axitinib) continued to demonstrate significant improvements in progression-free survival (PFS) and overall survival (OS) compared to Sutent (sunitinib) in patients with previously untreated, advanced RCC.
- A recent feature in CURE®’s Immunotherapy issue highlights how advances in a variety of novel treatments, including immunotherapies, are extending life in patients with advanced kidney cancer.
- Patients with advanced, previously untreated RCC may soon have a new option in the form of the novel combination of Opdivo (nivolumab) and Cabometyx (cabozantinib), according to study results from the phase 3 CheckMate-9ER trial.
- The Food and Drug Administration’s recent approval of a higher recommended dose of Keytruda (pembrolizumab) every six weeks for adults across all cancer types, in which the drug is indicated for, is a welcomed change for patients.
For more RCC coverage go
Advertisement
Related to this article
Five-year results presented at ASTRO 2026 show a five-week radiation schedule after prostatectomy controls cancer as well as a seven-week course. But serious urinary side effects were more common.
A study of more than 17,000 patients ages 23 to 64, presented at ASTRO 2026, found that only about 28% took endocrine therapy consistently for five years, and people who skipped radiation were more likely to fall off. Here's what to weigh before making that choice.
September brought new options for breast, lung, kidney, bile duct, skin and neuroendocrine cancers, plus a brain tumor scan and easier lung cancer treatment.
Dr. Nitin Ohri explains how radiation treats cancer, how often treatment is needed, common side effects and how to tell if radiation is working.
Ivonescimab outperformed Keytruda, a new myeloma drug lowered progression risk by 60% and more: the biggest phase 3 cancer results of September 2026.
Breast cancer treatment has changed dramatically since 2021. Here are the key FDA approvals, year by year, and what they mean for patients.
Choosing hospice care brought comfort, support and precious time for one family as they navigated cancer, caregiving and bringing a loved one home.
Advertisement
Advertisement
Trending on CURE
1
Hot Flashes From Breast Cancer Treatment May Soon Have an FDA-Approved Fix
2
The 5 Most Impactful Phase 3 Cancer Trial Results From September 2026
3
10 Cancer Treatment Approvals From September 2026 and What They Mean for You
4
Radiation Oncologist Answers Top Questions About Radiation Therapy
5